Fig. 11From: Therapeutic novelties in migraine: new drugs, new hope?Overview of the therapeutic gain* in percentage of patients with > 50% reduction in migraine days with anti-calcitonin gene-related peptide monoclonal antibodies. A darker bar indicates a higher dose. *Therapeutic gain is defined as the difference between percentage of patients in active group compared to percentage of patients in placebo groupBack to article page